Position in EYPT
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,784
-$1,367,466 QoQ
Shares Held
216
-99.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EYPT Over Time
Shares Held
Position Value (USD)
Derivatives in EYPT
reported options exposure · as of Mar 31, 2026CallValue
$1,002,842
CallShares
77,800
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Centiva Capital, LP holds $38,119,877 across 36 Biotechnology names. EYPT ranks #36 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,610 | $11,288,270 | |
| 2 | ABVX |
Abivax S.A.
|
57,150 | $6,363,652 | |
| 3 | TERN |
Terns Pharmaceuticals, Inc.
|
101,225 | $5,336,582 | |
| 4 | SLNO |
Soleno Therapeutics Inc
|
101,234 | $3,389,314 | |
| 5 | MANE |
Veradermics, Inc
|
20,000 | $1,263,000 | |
| 6 | INBX |
Inhibrx Biosciences, Inc.
|
17,739 | $1,192,592 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,147 | $958,721 | |
| 8 | CTMX |
CytomX Therapeutics, Inc.
|
200,000 | $940,000 |
All Filings in EYPT
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $1,002,842 | 77,800 | Call | Sole | 2026-05-14 | |
| 2026-03-31 | $2,784 | 216 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $3,593,709 | 196,700 | Call | Sole | 2026-02-13 | |
| 2025-12-31 | $1,370,250 | 75,000 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||